Shots:

• The EMA’s CHMP has recommended the approval of Alvotech‘s AVT02 (100 mg/mL)- a proposed biosimilar to Humira (adalimumab)  to treat AD in the EU
• The EC has been assigned to discuss the marketing authorization for AVT02. If approved- AVT02 will be extended to all EU member states along with other countries in the EEA- Iceland- Liechtenstein- and Norway
• Adalimumab is used to treat certain inflammatory conditions. Alvotech’s pipeline contains several mAb and fusion-protein biosimilar candidates that focus on autoimmunity- oncology- and inflammatory conditions to improve QoL for patients globally

  | Ref:  Businesswire  | Image: Businesswire